Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

Condition(s) studied

Investigational drug(s) / intervention(s)

observational study: This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Study summary

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Eligibility

Primary outcome measure(s)

• Number of participants that have achieved Low Disease Activity (LDA) at 12 months. — At 12 months
• Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months. — At 12 months
• Change from baseline in PROM scores at 12 months. — At 12 months

Trial sites (1)